跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 214 条关于
“Brooklyn Immunotherapeutics”
全部
214
临床试验
48
药物
38
机构
13
资讯
115
10个月前
Tempest Therapeutics Acquires Dual-CAR T Programs from Factor Bioscience in Strategic All-Stock Transaction
去年
Obicetrapib Shows Sustained LDL-C Reduction in HeFH Patients in Phase 3 Trial
去年
Brooklyn Health Raises $6.5M to Transform CNS Clinical Trial Measurement with AI-Powered Platform
去年
Obicetrapib Shows Promise in Lowering LDL Cholesterol and Lp(a) in HeFH Patients
去年
MoonLake Immunotherapeutics Reports Progress on Sonelokimab and Financial Results in Q3 2024
去年
Obicetrapib Demonstrates Significant LDL-C Reduction in HeFH Patients in Phase III BROOKLYN Trial
去年
OSE Immunotherapeutics Announces Positive H1 2024 Results and Corporate Updates
去年
OSE Immunotherapeutics Advances Global Phase 3 Trial for Cancer Vaccine Tedopi
2年前
Obicetrapib Shows Significant LDL-C Reduction in Phase 3 Trial for Heterozygous Familial Hypercholesterolemia
去年
MoonLake Immunotherapeutics Initiates Phase 3 Program for Sonelokimab in Psoriatic Arthritis
第 1 页,共 12 页
上一页
下一页